Sunovion: creating therapies to help transform people's lives_Home & Family

Skip to Main Content Product Innovation Product Innovation Pipeline Psychiatry" data-v-17bf0f17>Psychiatry Neurology Additional Therapies Scientific Publications Careers Careers Job Search Benefits Career Growth Partnerships Partnerships Submission Process Responsibility Responsibility Building Communities Advocating for Patients About Us About Us Mission, Vision & Values People & Culture Executive Leadership Diversity & Inclusion Contact Us News & Media News & Media Media Kit Health Care Professionals Patients Patient-Inspired Purpose. CNS Science-Driven Innovation. At Sunovion, we strive to serve and create value for patients every day. By developing innovative therapies that treat serious Central Nervous System (CNS) conditions, science leads the way—guiding us to a healthier tomorrow. Our News & Media News and Media" title="Homepage -> News and Media" class="l-card" data-v-132dd4d2>Jul 18, 2022 Taking on the future of medicine and mental health Slide 1 Slide 2 Slide 3 News and Media" title="Homepage -> News and Media" class="btn btn-icon btn-icon-arrow" data-v-132dd4d2>See all news About Us Discover Sunovion We are a patient-driven team with a strong track record of discovery, development and commercialization of important psychiatric and neurological therapies. We aim to improve the lives of people facing the enormous unmet needs associated with these serious conditions. Our passion drives us, our mission inspires us. About Us -> Learn more" title="Homepage -> About Us -> Learn more" class="btn btn-icon btn-icon-arrow btn--white" data-v-132dd4d2>Learn more Product Innovation Our Therapeutic Focus From our history of innovation to our future-forward approach to therapeutic advancements, we are committed to supporting people with serious psychiatric and neurological conditions live better lives. Today's developments pave the way for tomorrow's discoveries. Product Inovation -> Learn More" title="Homepage -> Product Inovation -> Learn More" class="btn btn-icon btn-icon-arrow" data-v-132dd4d2>Learn more Therapies in Development Uncover our latest developments as we expand our pipeline of innovative CNS therapies. Therapeutic Area Candidate Indication/Target Phase Psychiatry Ulotaront(SEP-363856) Schizophrenia Phase 3 75% complete Psychiatry SEP-4199 Bipolar Depression Phase 3 75% complete Neurology Ulotaront(SEP-363856) Parkinson’s disease psychosis Phase 2 50% complete Therapeutic Area Candidate Indication/Target Psychiatry Ulotaront(SEP-363856) Schizophrenia Phase 3 75% complete Psychiatry SEP-4199 Bipolar Depression Phase 3 75% complete Neurology Ulotaront(SEP-363856) Parkinson’s disease psychosis Phase 2 50% complete Product Inovation -> See the Full Pipeline" class="btn btn-icon btn-icon-arrow" data-v-132dd4d2>See full pipeline Responsibility Building Stronger Communities Sunovion is committed to working with partners to support the local, regional, and global community as part of our overall Corporate Social Responsibility efforts. Our collaboration with various community organizations helps in impactful ways to build stronger and healthier communities where we live and work. Responsibility -> Building Communities" class="btn btn-icon btn-icon-arrow btn--white mb-5 mb-md-0" data-v-132dd4d2>Read more Careers What’s Your Calling? What drives you? We believe that our work is a privilege. Every day we have an opportunity to apply our experiences and perspectives to create new treatments that will help people with serious medical conditions. Explore Careers" class="btn btn-icon btn-icon-arrow btn--green" data-v-132dd4d2>Explore careers What isSunovion Answers? We believe in putting people first, which is why we created Sunovion Answers. Our caring and skilled team is available to provide knowledge and resources to help patients, caregivers, family members, or providers. We're committed to finding solutions and connecting people to the information they need. Get answers from Sunovion" class="btn btn-icon btn-icon-arrow btn--white" data-v-132dd4d2>Get answers Product Innovation Careers Partnerships Responsibility About Us News & Media Patient Support SunovionSupport.com HCP Support SunovionProFile.com SunovionMedical.com Resources Procurement SunovionIISGrants.com SunovionIMEGrants.com Sumitomo Pharma Co., Ltd. Contact Us Terms of Use Privacy Policy & Cookie Notice Medical Disclaimer Social Media Community Guidelines Sources Sitemap Corporate Transparency Documents SUNOVION, , and LATUDA are registered trademarks of Sumitomo Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd. LUNESTA, , XOPENEX HFA, and BROVANA are registered trademarks of Sunovion Pharmaceuticals Inc. APTIOM is a registered trademark of , used under license. LONHALA and are registered trademarks of Sunovion Pharmaceuticals Inc. MAGNAIR is a registered trademark of PARI Pharma GmbH, used under license. eFlow and eLete are registered trademarks of PARI Pharma GmbH. KYNMOBI and are registered trademarks of Sunovion Pharmaceuticals Inc. © 2022 Sunovion Pharmaceuticals Inc. All rights reserved.